Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody

We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only...

Descripción completa

Detalles Bibliográficos
Autores principales: Funakoshi, Yohei, Yakushijin, Kimikazu, Ohji, Goh, Hojo, Wataru, Sakai, Hironori, Watanabe, Marika, Saeki, Miki, Hirakawa, Yuri, Sakai, Rina, Matsumoto, Sakuya, Mizutani, Yu, Kitao, Akihito, Miyata, Yoshiharu, Saito, Yasuyuki, Kawamoto, Shinichiro, Yamamoto, Katsuya, Ito, Mitsuhiro, Nishimura, Meiko, Imamura, Yoshinori, Kiyota, Naomi, Matsuoka, Hiroshi, Mori, Yasuko, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723797/
https://www.ncbi.nlm.nih.gov/pubmed/34981433
http://dx.doi.org/10.1007/s12185-021-03247-y
Descripción
Sumario:We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.

Ejemplares similares